UBS China Medtech: Expert Call Takeaways: Navigating China's Brain-Computer Interface Market
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
UBS hosted an expert call with a former product manager at a leading Chinese brain-computer interface (BCI) company to explore China's BCI market landscape. Non-invasive BCI products, primarily Class 1 and 2 medical devices used in rehabilitation, mental health assessment, sleep monitoring, and fatigue detection, are already commercially available, with more launches expected within 6–12 months.
Semi-invasive products, including traditional ECoG, flexible ECoG for higher-precision motor decoding, and brain-spinal cord interfaces enabling autonomous limb movement, are Class 3 devices expected to receive initial Chinese approval within 1–2 years. Fully invasive products targeting external robotic arm control, sensory restoration, and Parkinson's disease treatment may require 2–3 years for first approval.
China's BCI technology currently trails the United States by approximately two years, though the gap is expected to narrow significantly within two years. Neuralink achieves 1,024 channels versus 128–256 for Chinese products, and its implantable cursor click speed is roughly 20% faster than expert benchmarks, while domestic implantables are 20–30% slower than normal median users.
The expert estimates China's total BCI market could reach tens of billions of RMB by 2030, with non-invasive products capturing at least 70%. Non-invasive pricing ranges from approximately RMB 10,000 for sleep monitoring to RMB 2–4 million for exoskeleton-inclusive products. Leading domestic companies include Neuracle, PINS Medical, WE-LINKING, StairMed, and NeuCyber NeuroTech across different segments.